Garrett Laura D, Thamm Douglas H, Chun Ruthanne, Dudley Robert, Vail David M
Kansas State University Veterinary Medical Teaching Hospital, USA.
J Vet Intern Med. 2002 Nov-Dec;16(6):704-9. doi: 10.1892/0891-6640(2002)016<0704:eoacpw>2.3.co;2.
The purpose of this study was to compare a maintenance-free chemotherapy protocol based on CHOP (H from hydroxydaunorubicin = doxorubicin, O from Oncovin = vincristine) to a similar protocol with a maintenance phase for the treatment of canine lymphoma. Fifty-three dogs with multicentric lymphoma were treated with a 6-month modified version of the University of Wisconsin (UW)-Madison chemotherapy protocol (UW-25). Disease-free interval (DFI) and survival were compared to a historical control group of 55 dogs treated with a similar protocol with a prolonged maintenance phase. Remission rate for the study dogs was 94.2% (complete remission = 92.3%, partial remission = 1.9%). DFI and survival between the 2 groups did not differ significantly, with median DFI and survival of the study dogs equal to 282 and 397 days compared to 220 and 303 days for the control dogs (P = .2835 and .3365, respectively). Univariate analysis identified substage b (P = .0087), German Shepherd breed (P = .0199), and body weight > 18 kg (P = .0016) as significant for worse survival. Longer survival was associated with thrombocytopenia (P = .0436). Multivariate analysis revealed that substage (P = .0388) and weight (P = .0125) retained significance for DFI, whereas substage (P = .0093), thrombocytopenia (P = .0150), and weight (P = 0 .0050) retained significance for survival. Overall, the protocol was well tolerated by the dogs, with 41.5% (22/53) requiring a treatment delay or dose modification, but only 9.4% (5/53) needing hospitalization. The 6-month chemotherapy protocol based on CHOP with no maintenance phase provides similar DFI and survival times when compared to a similar protocol with a prolonged maintenance phase.
本研究的目的是比较基于CHOP方案（H代表羟基柔红霉素=多柔比星，O代表长春新碱=长春新碱）的无维持化疗方案与类似的含维持期方案治疗犬淋巴瘤的效果。53只患有多中心淋巴瘤的犬接受了威斯康星大学（UW）-麦迪逊化疗方案（UW-25）的6个月改良版治疗。将无病生存期（DFI）和生存率与55只接受类似方案且维持期延长的历史对照组犬进行比较。研究犬的缓解率为94.2%（完全缓解=92.3%，部分缓解=1.9%）。两组之间的DFI和生存率无显著差异，研究犬的中位DFI和生存期分别为282天和397天，而对照犬为220天和303天（P分别为0.2835和0.3365）。单因素分析确定分期b（P = 0.0087）、德国牧羊犬品种（P = 0.0199）和体重>18 kg（P = 0.0016）对较差的生存率有显著影响。血小板减少症与较长的生存期相关（P = 0.0436）。多因素分析显示，分期（P = 0.0388）和体重（P = 0.0125）对DFI仍具有显著意义，而分期（P = 0.0093）、血小板减少症（P = 0.0150）和体重（P = 0.0050）对生存率仍具有显著意义。总体而言，该方案犬的耐受性良好，41.5%（22/53）的犬需要延迟治疗或调整剂量，但只有9.4%（5/53）的犬需要住院治疗。与类似的含延长维持期方案相比，基于CHOP且无维持期的6个月化疗方案提供了相似的DFI和生存时间。
